We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From May 2019 to May 2024
Mylan NV's (MYL) shares fall 5% to $39.65 in after-hours trading Wednesday after the drugmaker says in a regulatory filing that U.S. health regulators have found "minor deficiencies" in its proposed generic version of GlaxoSmithKline PLC's asthma blockbuster Advair. The Food & Drug Administration is to send Mylan the rejection notice, called a complete response letter, on June 27. Mylan, which didn't offer any details on the deficiencies found, said it would then determine if it needs to adjust its 2018 forecast. (maria.armental@wsj.com; @mjarmental)
(END) Dow Jones Newswires
June 13, 2018 20:16 ET (00:16 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
